12,372 trials
Lupus Nephritis
Primary: Double-blind Period: Percentage of Participants With Primary Efficacy Renal Response (PERR) at Week 104 — 32.3; 43.0 Percentage of participants — p=0.0311
Pregnant Women · Pain · Hypotension
Primary: Time to Regression of Motor Block — 180; 130 minutes
Migraine, With or Without Aura
Primary: Number of Participants With SAEs and AEs Leading to Discontinuation During the Treatment Period — 664; 315; 109; 108 Participants
Migraine
Primary: Headache Days — 23.64; 24.33 Days — p=0.83
Duchenne Muscular Dystrophy (DMD)
Primary: Change From Baseline in the 6 Minute Walk Test (6MWT) Distance at Week 96 — -117.91; -133.56 meters
Uterine Fibroids · Heavy Menstrual Bleeding
Primary: Percentage of Participants Meeting the Criteria for Responder — 85.7; 66.7; 89.4; 87.9 percentage of participants
Uterine Fibroids · Heavy Menstrual Bleeding
Primary: Percentage of Participants Meeting the Criteria for Responder — 10.5; 76.9; 76.5 percentage of participants — p=< 0.001
Multiple Sclerosis
Primary: Percentage of Participants With Infusion-related Reaction (IRR) Treated With 600 mg IV Ocrelizumab — 0 Percentage of Participants
Heart Failure · Chronic Heart Failure With Reduced Ejection Fraction
Primary: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization — 33.6; 37.8 Parts w/ event per 100 part-yrs at risk…
Inflammation and Pain Associated With Cataract Surgery
Primary: Proportion of Participants With Anterior Chamber Cell (ACC) Grade 0 in Study Eye at Day 15 (Last Observation Carried Forward) in the Modified Intent to Treat (mITT)…
Pneumococcal Infections
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event — 10.7; 11.6; 68.5; 71.1 Percentage of Participants — p=0.617
Uterine Fibroids · Heavy Menstrual Bleeding
Primary: Percentage of Participants Meeting the Criteria for Responder — 8.7; 84.1; 68.5 percentage of participants — p=< 0.001
Constipation · Chronic Idiopathic Constipation · CIC
Primary: Treatment Response — 77; 39 Participants — p=<0.001
Constipation · Chronic Idiopathic Constipation · CIC
Primary: % of Subjects With Treatment Emergent Adverse Events — 108 Participants
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 16.39; 14.69 Months — p=0.0752